Akdital operates private healthcare clinics. The company offers healthcare services such as cardiac surgery, neurosurgery, oncology, radiotherapy, intensive care, and neonatal care, providing patients with comprehensive care according to international standards.
2016
2.7K+
LTM Revenue $322M
LTM EBITDA $90.4M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akdital has a last 12-month revenue of $322M and a last 12-month EBITDA of $90.4M.
In the most recent fiscal year, Akdital achieved revenue of $104M and an EBITDA of $28.1M.
Akdital expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Akdital valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $76.8M | $104M | $305M | $322M | XXX |
Gross Profit | n/a | $45.0M | $54.5M | XXX | XXX |
Gross Margin | NaN% | 43% | 18% | XXX | XXX |
EBITDA | $19.6M | $28.1M | $85.0M | $90.4M | XXX |
EBITDA Margin | 26% | 27% | 28% | 28% | XXX |
Net Profit | n/a | $4.4M | $8.8M | XXX | XXX |
Net Margin | NaN% | 4% | 3% | XXX | XXX |
Net Debt | n/a | $37.8M | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, Akdital's stock price is MAD n/a (or $n/a).
Akdital has current market cap of MAD 13.3B (or $1.3B), and EV of MAD 14.2B (or $1.4B).
See Akdital trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.4B | $1.3B | XXX | XXX | XXX | XXX | $2.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, Akdital has market cap of $1.3B and EV of $1.4B.
Akdital's trades at 4.4x LTM EV/Revenue multiple, and 15.8x LTM EBITDA.
Analysts estimate Akdital's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Akdital and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $1.4B | XXX | XXX | XXX |
EV/Revenue | 4.7x | XXX | XXX | XXX |
EV/EBITDA | 16.8x | XXX | XXX | XXX |
P/E | 43.8x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -20.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAkdital's NTM/LTM revenue growth is 48%
Akdital's revenue per employee for the last fiscal year averaged $38K, while opex per employee averaged $14K for the same period.
Over next 12 months, Akdital's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Akdital's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Akdital and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 195% | XXX | XXX | XXX | XXX |
EBITDA Margin | 28% | XXX | XXX | XXX | XXX |
EBITDA Growth | 202% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 76% | XXX | XXX | XXX | XXX |
Revenue per Employee | $38K | XXX | XXX | XXX | XXX |
Opex per Employee | $14K | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | 36% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akdital acquired XXX companies to date.
Last acquisition by Akdital was XXXXXXXX, XXXXX XXXXX XXXXXX . Akdital acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Akdital founded? | Akdital was founded in 2016. |
Where is Akdital headquartered? | Akdital is headquartered in Morocco. |
How many employees does Akdital have? | As of today, Akdital has 2.7K+ employees. |
Is Akdital publicy listed? | Yes, Akdital is a public company listed on CAS. |
What is the stock symbol of Akdital? | Akdital trades under AKT ticker. |
When did Akdital go public? | Akdital went public in 2022. |
Who are competitors of Akdital? | Similar companies to Akdital include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
What is the current market cap of Akdital? | Akdital's current market cap is $1.3B |
What is the current revenue of Akdital? | Akdital's last 12-month revenue is $322M. |
What is the current EBITDA of Akdital? | Akdital's last 12-month EBITDA is $90.4M. |
What is the current EV/Revenue multiple of Akdital? | Current revenue multiple of Akdital is 4.4x. |
What is the current EV/EBITDA multiple of Akdital? | Current EBITDA multiple of Akdital is 15.8x. |
What is the current revenue growth of Akdital? | Akdital revenue growth between 2023 and 2024 was 195%. |
Is Akdital profitable? | Yes, Akdital is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.